Developing new tools for discovering cancer drugs
Official title: New Chemical Tools for Covalent Drug Discovery
Funded at Dana-Farber Cancer Inst · NIH-11018610 · Data updated 2026-11-12
This study is all about developing new tools to see how cancer drugs work with proteins in the body, which could help make these treatments safer and more effective for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $249,647 |
| NIH project number | 5R61CA278449-02 |
| Project ID | NIH-11018610 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancer who may benefit from new therapeutic options.
✕Less likely to help
Patients who are not currently undergoing cancer treatment or those with non-cancerous conditions may not receive any benefit from this research.
What this research studies
This research focuses on creating new chemical tools that help identify how cancer drugs interact with proteins in the body. By understanding which proteins are targeted by these drugs and how they bind to them, researchers aim to improve the safety and effectiveness of cancer therapies. The team will synthesize and test these tools to gather important data on drug interactions, which can lead to better risk assessments and more promising drug candidates for clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer treatments.
How similar studies have gone: Other research has shown promise in using similar chemical tools for drug discovery, indicating a potential for success in this approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Marto, Jarrod a. — Dana-Farber Cancer Inst
- Study coordinator: Marto, Jarrod a.
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.